NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ring Therapeutics

Ring Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://ringtx.com/

Last Round

Series C

Mar 9, 2023

Total Funding Raised

$253.5M

Company Overview

Ring Therapeutics is a biotechnology company that develops programmable medicines utilizing a novel viral vector platform based on the human commensal virome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyanellovirusviral vectorbiomanufacturinggenetic diseasevector engineeringdrug deliverybiotech startuptherapeutic deliveryclinical-stage biotechgene deliverybiotech R&Dnext-gen gene therapyviral vector platformbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ring Therapeutics Comparables

Compare Ring Therapeutics with similar companies based on industry and business-model similarity.

Ring Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Capsida Biotherapeutics
80%
Senda Biosciences
80%
Vector BioPharma
77%

Ring Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 9, 2023
Series BJul 28, 2021
Series ADec 19, 2019

Key People

Founding team and executive leadership

Chris McNulty

Interim CEO

Executive Team

Tuyen Ong

Chief Executive Officer

Executive Team

Ring Therapeutics Investors

Notable investors and investment history

Ring Therapeutics investors
InvestorRounds
Altitude Life Science VenturesSeries B, Series C
Invus OpportunitiesSeries C, Series B
CJ InvestmentSeries C
T. Rowe PriceSeries C, Series B
Alexandria Venture InvestmentsSeries C
UPMC EnterprisesSeries C, Series B
Partners InvestmentSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 14, 2025

    New data shows successful infectivity and expression of AnelloVectors.

  • May 14, 2025

    Presented new data at the ASCGT Conference in New Orleans.

Ring Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ring Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ring Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range45
Year Founded2017
Last FundingMar 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.